Hydromorphone ( DrugBank: Hydromorphone )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 70 | Spinal stenosis | 1 |
70. Spinal stenosis
Clinical trials : 95 / Drugs : 169 - (DrugBank : 61) / Drug target genes : 68 - Drug target pathways : 90
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03088306 (ClinicalTrials.gov) | July 1, 2017 | 22/2/2017 | Improving Pain and Reducing Opioid Use (IPaRO) in Lumbar Spine Surgery Patients | Comparative Effectiveness of Multi-modal Pain Management Versus Standard Intra- and Post-operative Analgesia: Randomized Controlled Clinical Trial to Reduce Post-operative Pain and Opioid Use Among Patients Undergoing Lumbar Spine Surgery | Lumbar Spinal Stenosis;Lumbar Spinal Instability;Lumbar Spine Degeneration | Drug: Standard analgesia use [Oxygen];Drug: Standard analgesia use [Hydromorphone];Drug: Standard analgesia use [Volatile Anesthesia];Drug: Standard analgesia use [Fentanyl];Drug: Multi-modal pain management [Acetaminophen + Gabapentin];Drug: Multi-modal pain management [Fentanyl];Drug: Multi-modal pain management [Intravenous Ketamine];Drug: Multi-modal pain management [Valium + Gabapentin] | Johns Hopkins University | North American Spine Society | Completed | 18 Years | 100 Years | All | 49 | Early Phase 1 | United States |